Anteris Technologies Global (AVR) vs Delcath Systems (DCTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Anteris Technologies Global (AVR) has outperformed Delcath Systems (DCTH) over the past year, gaining 38.7% versus a gain of 35.5%. Anteris Technologies Global is the larger company by market cap ($662.7 million vs $522.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVR | DCTH |
|---|---|---|
| Share price | $6.80 | $15.07 |
| Market cap | $662.72M | $522.91M |
| 1-day change | +2.56% | +0.20% |
| YTD return | +32.87% | +48.91% |
| 1-year return | +38.70% | +35.50% |
| 5-year return | — | +59.83% |
| Forward P/E | — | 334.89 |
| EPS (TTM) | $-1.95 | $0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.06 | $17.42 |
| 52-week low | $3.30 | $8.12 |
| Distance from 52-week high | -38.49% | -13.49% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +105.88% | +59.26% |
| Average volume | 935.07K | 479.73K |
| Shares outstanding | 97.46M | 34.70M |
| Employees | 174 | 156 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Anteris Technologies Global
AVR stock →Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.
Health Care · Industrial Specialties · 174 employees
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Health Care · Medical/Dental Instruments · 156 employees
AVR vs DCTH FAQ
Which is bigger, Anteris Technologies Global or Delcath Systems?
Anteris Technologies Global (AVR) is larger, with a market capitalization of $662.72M compared with $522.91M for Delcath Systems (DCTH).
Which stock has performed better over the past year, AVR or DCTH?
AVR returned +38.70% over the past 12 months, compared with +35.50% for DCTH (price return, excluding dividends). Past performance does not predict future results.
Are Anteris Technologies Global and Delcath Systems in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Anteris Technologies Global and Medical/Dental Instruments for Delcath Systems.